Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes.

Frontiers in endocrinology·2026
Same author

Corrigendum to Correction of diabetes mellitus by transplanting minimal mass of syngeneic islets into vascularized small intestinal segment American Journal of Transplantation. Volume 13, Issue 10, October 2013, Pages 2550-2557.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Protocol to study regeneration in human pancreatic slices using viral tracing, extended culture, dissociation, and functional Ca<sup>2+</sup> influx techniques.

STAR protocols·2026
Same author

Optimizing 3D-printed Scaffold Geometry Decreases Foreign Body Response and Enhances Allogeneic Islet Transplant Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

β-Cell Neogenesis From the Pancreatic Ductal Epithelium Revealed Dynamically by Long-term Intravital Imaging.

Diabetes·2025
Same author

Pancreatic Islet Transplantation in Extrahepatic Sites: Evaluation of the Venous Sac in Large Mammal Models.

Diabetes & metabolism journal·2025

Related Experiment Video

Updated: May 16, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

Concise review: mesenchymal stem cells for diabetes.

Juan Domínguez-Bendala1, Giacomo Lanzoni, Luca Inverardi

  • 1Diabetes Research Institute.

Stem Cells Translational Medicine
|December 1, 2012
PubMed
Summary

Mesenchymal stem cells (MSCs) show promise for treating type 1 diabetes by generating insulin-producing beta-cells. Further research is needed, but reprogramming advances offer hope for personalized diabetes therapies.

More Related Videos

Isolation and Identification of Mesenchymal Stem Cells Derived from Adipose Tissue of Sprague Dawley Rats
10:50

Isolation and Identification of Mesenchymal Stem Cells Derived from Adipose Tissue of Sprague Dawley Rats

Published on: April 7, 2023

Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells
08:09

Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells

Published on: August 29, 2022

Related Experiment Videos

Last Updated: May 16, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

Isolation and Identification of Mesenchymal Stem Cells Derived from Adipose Tissue of Sprague Dawley Rats
10:50

Isolation and Identification of Mesenchymal Stem Cells Derived from Adipose Tissue of Sprague Dawley Rats

Published on: April 7, 2023

Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells
08:09

Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells

Published on: August 29, 2022

Area of Science:

  • Regenerative Medicine
  • Immunology
  • Endocrinology

Background:

  • Mesenchymal stem cells (MSCs) are a versatile cell source for regenerative medicine, derived from adult tissues without ethical concerns.
  • Type 1 diabetes mellitus is an autoimmune disease targeting pancreatic beta-cells, leading to insulin deficiency.
  • Current treatments for type 1 diabetes are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review the potential of MSCs for treating type 1 diabetes.
  • To analyze advances in differentiating MSCs into functional beta-cells for therapeutic use.
  • To evaluate MSC potency based on their tissue of origin for diabetes treatment.

Main Methods:

  • Review of current literature on MSC differentiation protocols for beta-cell generation.
  • Analysis of MSC potency and suitability for islet transplantation in type 1 diabetes.
  • Discussion of recent breakthroughs in cell reprogramming relevant to MSC-based therapies.

Main Results:

  • MSCs offer a potential source for generating insulin-producing beta-cells to restore pancreatic islet mass.
  • MSC differentiation protocols are advancing, but no single method is currently ready for clinical trials.
  • MSC potency varies depending on the tissue of origin, influencing their therapeutic potential.

Conclusions:

  • MSCs hold significant promise as a cell source for developing personalized therapies for type 1 diabetes.
  • Advances in cell reprogramming are overcoming previous limitations in generating beta-cells from different cell types.
  • Further development of MSC differentiation protocols is crucial for clinical application in type 1 diabetes treatment.